Loading...
Market
What will be the FDA's decision on Neurocrine's NBI-1117568 by end of 2025?
4
Resolution / Starting Odds
Approved at 20 mg dose • 25%
Approved at higher dose • 25%
Approved at multiple doses • 25%
Not approved • 25%
FDA approval announcements or Neurocrine Biosciences' press releases
Story
Neurocrine's Schizophrenia Drug Shows 7.5 Point Improvement in Phase 2 Trial; Shares Drop 15.6%
Aug 28, 2024, 11:33 AM
Neurocrine Biosciences has announced positive results from a mid-stage Phase 2 study of its experimental drug NBI-1117568 for treating schizophrenia in adults. The study achieved its main goal, showing a 7.5 point improvement on the PANSS score with a 20 mg daily dose, which was statistically significant. However, no improvement was observed with higher doses. Despite the positive outcome, the company's shares have dropped by 15.6% in pre-market trading as investors reacted to the mixed results of the trial.
View original story
Similar markets
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Approval • 33%
Rejection • 33%
Request for more data • 34%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Yes • 50%
No • 50%
Approved • 33%
Rejected • 33%
Request for more data • 34%
Approved for all indications • 25%
Approved for some indications • 25%
Not approved • 25%
Approval delayed • 25%
Approved without conditions • 25%
Approved with conditions • 25%
Rejected • 25%
No decision by deadline • 25%
Approved without conditions • 25%
Approved with conditions • 25%
Approval delayed • 25%
Not approved • 25%
